Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival? - Université de Reims Champagne-Ardenne Access content directly
Journal Articles Frontiers in Oncology Year : 2022

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?

Abstract

OS and DFS (p=<0.001). R0 patients had significantly longer OS (p=0.03) and longer DFS (P=0.08). In the multivariate analysis, the presence of postoperative pancreatic fistula, R1 resection, N+ and not access to adjuvant chemotherapy were bad prognostic factors of OS. Conclusions: Our study suggests the benefits of NAC for BR patients in downstaging tumors and rendering them amenable to resection, with same oncological result compared to US.
Fichier principal
Vignette du fichier
fonc-12-980659.pdf (1.19 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-04099959 , version 1 (17-05-2023)

Licence

Identifiers

Cite

Violette Fossaert, Antonio Mimmo, Rami Rhaiem, Linda J Rached, Mathilde Brasseur, et al.. Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?. Frontiers in Oncology, 2022, 12, ⟨10.3389/fonc.2022.980659⟩. ⟨hal-04099959⟩

Collections

URCA BIOSPECT
15 View
38 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More